Exploratory study of hereditary porphyria diagnosis by porphyrin intermediate metabolite specific spectrum detection using liquid crystal tunable filter (LCTF)

Exploratory study of hereditary porphyria diagnosis by porphyrin intermediate metabolite specific spectrum detection using liquid crystal tunable filter (LCTF) - Exploratory study of hereditary porphyria diagnosis by liquid crystal tunable filter (LCTF)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036114

Enrollment

Registered

2019-03-06

Start date

2019-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hereditary porphyria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who satisfy all the following criteria are targeted. 1) Clinically suspected of porphyria 2) Persons who have already been confirmed for genetic porphyria already by gene / HPLC etc.

Exclusion criteria

Exclusion criteria: Patients who conflict with one of the following will not be included in this clinical study. 1) Patients with lead poisoning, liver diseases such as liver cirrhosis / liver cancer, blood diseases such as iron deficiency anemia and sideroblastic anemia, hypermetabolism, endocrine diseases 2) Patients suspected of elemental poisoning such as arsenic and mercury. 3) Patients suspected of intoxication of polyaromatic halide compounds such as dioxin and PCB. 4) Patients taking phenobarbital, cedlumide, griseofulvin, carbamazepine 5) Others who the research researcher deems inappropriate as a patient.

Design outcomes

Primary

Measure	Time frame
The differential diagnosis of hereditary porphyria (especially, VP, HCP, EPP) by detecting the intrinsic fluorescence spectra of porphyrin intermediate metabolites (Uro III, Copro - III, Pp - IX) in urin/stool samples using LCTF	—

Secondary

Measure	Time frame
1)Correlation between intrinsic fluorescence spectrum of porphyrin intermediate metabolite and results of HPLC analysis, genetic test(previously obtained). 2)Discrimination of difference in detectability by various clinical samples (urine/stool) 3)Correlation between intrinsic fluorescence spectrum of porphyrin intermediate metabolite and clinical data (gender, age, blood biochemistry data)	—

Countries

Japan

Contacts

Public ContactTakaaki Suighara

Tottori University Faculty of Medicine Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, School

sugitaka@tottori-u.ac.jp0859386527

Outcome results